Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.19.3
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 11, 2015
Jun. 30, 2019
Sep. 30, 2018
May 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Mar. 31, 2015
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2017
Neupharma [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Payment of Upfront Fees             $ 1,000,000              
Reimbursement Of Cost Recognized As Revenue                   $ 0 $ 31,000      
Neupharma [Member] | Additional Sales Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum Potential Milestone Payments               $ 40,000,000   40,000,000        
Neupharma [Member] | Clinical and Development Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum Potential Milestone Payments               40,000,000   40,000,000        
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum Potential Milestone Payments               22,500,000   22,500,000        
Dana-Farber [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Shares Issued, Price Per Share $ 0.065                          
Stock Issued During Period, Shares, Issued for Services 500,000         136,830                
Stock Issued During Period, Value, Issued for Services $ 32,500         $ 600,000                
Payment of Upfront Fees             1,000,000              
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 5.00%                          
Cash In Exchange For Common Stock $ 10,000,000                          
Payment For Non refundable Milestone payments     $ 1,000,000                      
Maintenance Fee                       $ 50,000    
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               28,600,000   28,600,000        
Maximum Potential Milestone Payments               21,500,000   21,500,000        
Dana-Farber [Member] | Additional Sales Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               60,000,000   60,000,000        
Maximum Potential Milestone Payments               60,000,000   60,000,000        
Dana-Farber [Member] | Commercial Sales In Specified Territories [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               21,500,000   21,500,000        
Teva Pharmaceutical Industries Ltd [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Payment of Upfront Fees         $ 500,000                  
Jubilant Biosys Ltd [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Payment of Upfront Fees                         $ 2,000,000  
Revenue Recognition, Milestone Method, Revenue Recognized               $ 13,000 $ 5,000 $ 37,000 399,000      
Research and Development Cost, Shared Percentage               50.00%   50.00%        
Non-Refundable Milestone Payment                           $ 400,000
Proceeds from Upfront Fees       $ 1,000,000                    
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum Potential Milestone Payments               $ 89,000,000   $ 89,000,000        
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum Potential Milestone Payments               59,500,000   59,500,000        
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               61,700,000   61,700,000        
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               89,000,000   89,000,000        
Maximum Potential Milestone Payments               89,000,000   89,000,000        
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               87,200,000   87,200,000        
Adimab LLC [Member] | Clinical and Development Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum Potential Milestone Payments               7,100,000   7,100,000        
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Maximum Potential Milestone Payments               4,800,000   4,800,000        
Collaboration Agreement With TGTX [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Payment of Upfront Fees   $ 1,000,000                        
Revenue Recognition, Milestone Method, Revenue Recognized               300,000 $ 0 1,600,000 $ 44,000      
Proceeds from Upfront Fees             $ 500,000              
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               7,000,000   7,000,000        
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               14,500,000   14,500,000        
Collaboration Agreement With TGTX [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               19,200,000   19,200,000        
Collaboration Agreement With TGTX [Member] | Clinical Development and Regulatory Milestones [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               9,400,000   9,400,000        
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenue Recognition Milestone Method, Payments Due               $ 25,500,000   $ 25,500,000